Hypercortisolemia and glucocorticoid receptor-signaling insufficiency in Alzheimer's disease initiation and development

Current Alzheimer Research

Volumn 10, Issue 7, 2013, Pages 714-731

  Notarianni, Elena ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

Author keywords

amyloid; Alzheimer's disease; Corticotropin releasing hormone; Cortisol; Glucocorticoid receptor; Hypothalamic pituitary adrenal axis; Stress; Tau

Indexed keywords

ADENYLATE CYCLASE; CANDESARTAN; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUTAMIC ACID; HYDROCORTISONE; HYDROGEN PEROXIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MIFEPRISTONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PRESENILIN 1; PRESENILIN 2; PROOPIOMELANOCORTIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADRENALECTOMY; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; AMYLOID PLAQUE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BASAL CISTERN; BLOOD SAMPLING; BRAIN CELL; BRAIN CORTEX; BRAIN REGION; CALORIC RESTRICTION; CATALYSIS; CELL DIFFERENTIATION; CELL VIABILITY; CENTRAL NUCLEUS (AMYGDALA); CIRCADIAN RHYTHM; COGNITION; COGNITIVE DEFECT; COGNITIVE RESERVE; CORTICOSTERONE RELEASE; CUSHING DISEASE; DEMENTIA; DEXAMETHASONE SUPPRESSION TEST; DIABETES MELLITUS; DIET RESTRICTION; DISEASE COURSE; ENZYME ACTIVITY; FEEDBACK SYSTEM; GABAERGIC SYSTEM; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HOMEOSTASIS; HORMONE SYNTHESIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERACTIVITY; HYPERCORTISOLISM; HYPERTENSION; IMMOBILIZATION STRESS; IMMUNOREACTIVITY; INTERNEURON; LONG TERM EXPOSURE; MAJOR DEPRESSION; MOTOR CORTEX; NEGATIVE FEEDBACK; NERVE CELL CULTURE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NORADRENERGIC SYSTEM; OXIDATIVE STRESS; PATHOGENESIS; PERIODICITY; PERIRHINAL CORTEX; PLEIOTROPY; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; RECEPTOR DOWN REGULATION; RECURRENT INFECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TRANSCRIPTION INITIATION; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CIRCADIAN RHYTHM; CUSHING SYNDROME; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84888222160     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990137     Document Type: Article

References (218)

1. Thal DR, Arendt T, Waldmann G, Holzer M, Zedlick D, Rüb U, et al. Progression of neurofibrillary changes and PHF-T in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology. Neurobiol Aging 19: 517-525 (1998).
2. Thal DR, Rüb U, Orantes M, Braak H. Phases of Aβ deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800 (2002).
3. Alzheimer A. Über eine eigenartige Erkrangkung der Hirnrinde, Allegemeine Zeitschrift für Psychiatrie und psychisch-gerichtliche Medizin (Berlin). 64: 146-148 (1907).
4. Fischer O. Miliare Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmässige Veränderung der Hirnrinde bei seni-ler Demenz. Monatsschr Psychiat Neurol 22: 361-372 (1907).
5. Bao AM, Meynen G, Swaab FF. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev 57: 531-553 (2008).
6. Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 76: 1395-1402 (2011).
7. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 58: 1188-1196 (2002).
8. Raz N, Rodrigue KM, Head D, Kennedy KM, Acker JD. Differential aging of the medial temporal lobe: a study of a five-year change. Neurology 62: 433-438 (2004).
9. Du A-T, Schuff N, Chao LL, Kornak J, Jagust WJ, Kramer JH, et al. Age effects on atrophy rates of entorhinal cortex and hippocampus. Neurobiol Aging 27: 733-740 (2006).
10. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Ap and synaptic dysfunction. Neuron 39: 409-421 (2003).
11. Nagy Z, Hindley NJ, Braak H, Braak E, Yilmazer-Hanke DM, Schultz C, et al. Relationship between clinical and radiological diagnostic criteria for Alzheimer's disease and the extent of neuropathology as reflected by 'Stages': a prospective study. Dementia Geriatric Cogn Dis 10: 109-114 (1999).
12. Taylor KI, Probst A. Anatomic localization of the transentorhinal region of the perirhinal cortex. Neurobiol Aging 29: 1591-1596 (2008).
13. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 121: 171-181 (2011).
14. Nagy Z, Hindley NJ, Braak H, Braak E, Yilmzer-Hanke DM, Schultz C, et al. The progression of Alzheimer's disease from limbic regions to the neocortex; clinical, radiological and pathological relationships. Dementia Geriatric Cogn Dis 10: 115-120 (1999).
15. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 24: 321-331 (2003).
16. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron 66: 631-645 (2011).
17. Van de Nes JAP, Sluiter AA, Pool CW, Kamphorst W, David R, Swaab D. The monoclonal antibody Alz-50, used to reveal cy-toskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas. Brain Res 655: 97-109 (1994).
18. Van de Nes JAP, Kamphorst W, David R, Swaab DF. Comparison of p-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol 896: 129-138 (1998).
19. rd series, Vol 2). Amsterdam, Elsevier pp. 313-349 (2004).
20. Ajit D, Udan MLD, Paranjape G, Nichols MR. Amyloid-p(1-42)fibrillar precursors are optimal for inducing tumor necrosis fac-tor-a production in the THP-1 human monocytic cell line. Biochemistry 48: 9011-21 (2009).
21. Janelsins MC, Mastrangelo MA, Oddo S, LaFerla F, Federoff HJ, Bowers WJ. Early correlation of miciroglial activation with enhanced tumor necrosis factor alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflamm 2: 23-35 (2005).
22. Craft JM, Watterson M, van Eldik LJ. Human amyloid p-induced neuroinflammation is an early event in neurodegeneration. Glia 53: 484-90 (2006).
23. Krause DL, Muller N. Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Int J Alzhimer's Dis Volume 2010: Article ID 732806, 9 pages.
24. Behl C, Lezoualc'h F, Trapp T, Widmann M, Skutella T, Holsboer F. Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology 138: 101-106 (1997).
25. Behl C, Trapp T, Skutella T, Holsboer F. Protection against oxidative stress-induced neuronal cell death - a novel role for RU486. Eur J Neurosci 9: 912-20 (1997).
26. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP. Amyloid p-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of lipidperoxidation. J Neurosci 17: 1046-1054 (1997).
27. Takeda A, Smith MA, Avila J, Nunomura A, SL Siedlak, Zhu X, et al. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of x induced by 4-hydroxy-2-nonenal modification. J Neurochem 75: 1231-1241 (2000).
28. Ohm TG, Schmitt M, Bohl J, Lemmer B. Decrease in adenylate cyclase activity antecedes neurofibrillary tangle formation. Neurobiol Aging 18: 275-279 (1997).
29. Davis KL, Mohs RC, Marin DB, Dushyant P, Purohit MD, Perl DP, et al. Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry 56: 981-987 (1999).
30. Kadir A, Marutle A, Gonzalez D, Scholl M, Almkvist O, Mousavi M, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 134: 301-317 (2011).
31. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems in the road to therapeutics. Science 297: 353-356 (2002).
32. Tol J, Roks G, Slooter AJ, van Duijn CM. Genetic and environmental factors in Alzheimer's disease. Rev Neurol 155: Suppl 4:S10-S16 (1999).
33. Green KN, Billings LM, Rozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-p and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 26: 9047-9056 (2006).
34. Sleegers K, Roks G, Theuns J, Aulchenko YS, Rademakers R, Cruts M, et al. Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. Brain 127: 1641-1649 (2004).
35. Blacker D, Haines JL, Rodes L, Terwedow H, Go RCP, Harrell LE, et al. ApoE-4 and age at onset of Alzheimer' disease. Neurology 48: 139-147 (1997).
36. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epige-netic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14: 992-1003 (2009).
37. Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JS, Bennett DA. Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology 61: 1479-1485 (2003).
38. Wilson RS, Bennett DA, Mendes de Leon CF, Bienias JL, Morris MC, Evans DA. Distress proneness and cognitive decline in a population of older persons. Psychoneuroendocrinol 30: 11-17 (2005).
39. Rissman RA. Stress-induced tau phosphorylation: functional neu-roplasticity or neuronal vulnerability? J Alzheimer's Dis 18: 453-457 (2009).
40. Rothman SM, Mattson MP. Adverse stress, hippocampal networks, and Alzheimer's disease. Neuromolecular Med 12: 56-70 (2010).
41. Sotiropoulos I, Catania C, Pinto LG, Silva R, Pollerberg E, Taka-shima A, et al. Stress acts cumulatively to precipitate Alzheimer's disease-like TAU pathology and cognitive defects. Neurobiol Dis 31: 7840-7847 (2011).
42. Mejia S, Giraldo M, Pineda D, Ardila A, Lopera F. Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease. Int Psychogeriatr 15: 337-349 (2003).
43. De Quervain D J-F, Poirier R, Wollmer MA, Grimaldi LME, Tso-laki M, Streffer JR, et al. Glucocorticoid-related genetic susceptibility for Alzheimer's disease. Hum Mol Genet 13: 47-52 (2004).
44. Van Rossum EFC, de Jong FJ, Koper JW, Utterlinden AG, Prins ND, van Dijk EJ, et al. Glucocorticoid receptor variant and risk of dementia and white matter lesions. Neurobiol Aging 29: 716-723 (2008).
45. Kehoe PG. The renin-angiotensin-aldosterone system and Alzheimer's disease? J Renin Angiotensin Aldosterone Syst 4: 80-93 (2003).
46. Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS, et al. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J 20: 729-31 (2006).
47. Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-p via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci USA 104: 10673-10678 (2007).
48. Catania C, Sotiropoulos I, Silva R, Onofri C, Breen KC, Sousa N, et al. The amyloid potential and behavioural correlates of stress. Mol Psychiatry 14: 95-105 (2009).
49. Ray B, Gaskins DL, Sajdyk TJ, Spence JP, Fitz SD, Shekhar A, et al. Restraint stress and repeated corticotrophin-releasing factor receptor activation in the amygdala both increase amyloid-p precursor protein and amyloid- β peptide but have divergent effects on brain-derived neurotrophic factor and presynaptic proeins in the prefrontal cortex of rats. Neuroscience 184: 139-150 (2011).
50. Rissman RA, Lee K-F, Vale W, Sawchenko PE. Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. J Neurosci 27: 6552-6562 (2007).
51. Zhang LF, Shih L, Liu H, Meng FT, Liu YJ, Wu HM, et al. Increased hippocampal tau phosphorylation and axonal mitochondrial transport in a mouse model of chronic stress. Int J Neuropsycho-pharmacol 15: 337-348 (2012).
52. Giubilei F, Patacchioli FR, Antonini G, Sepe MM, Tisei P, Basti-anello S, et al. Altered circadian cortisol secretion in Alzheimer's disease: clinical and neuroradiological aspects. J Neurosci Res 66: 262-265 (2001).
53. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ul-tradian secretory pulsatility and diurnal variation. Neurobiol Aging 18: 285-289 (1996).
54. Swanwick GRJ, Kirby M, Bruce I, Buggy F, Coen RF, Coakley D, et al. Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry 155: 286-289 (1998).
55. Umegaki H, Ikari H, Nakahata H, Endo H, Suzuki Y, Ogawa O, et al. Plasma cortisol levels in elderly female subjects with Alzheimer's disease. Brain Res 881: 241-243 (2000).
56. Weiner MF, Vobach S, Svetlik D, Risser RC. Cortisol secretion and Alzheimer's disease progression; a preliminary report. Biol Psychiatry 34: 158-161(1993).
57. Weiner MF, Vobach S, Olsson K, Svetlik D, Risser RC. Cortisol secretion and Alzheimer's disease progression. Biol Psychiatry 42: 1030-1038 (1997).
58. Linder J, Nolgard P, Nassman B, Udhammer A, Olsson T. Decreased peripheral glucocorticoid sensitivity in Alzheimer's disease. Gerontology 39: 200-206 (1993).
59. Franceschi M, Airaghu L, Gramignana C, Truci G, Manfredi MG, Canal N, et al. ACTH and cortisol secretion in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatr 54: 836-837 (1991).
60. Nasman B, Olsson T, Seckl JR, Eriksson S, Viitanen M, Bucht G, et al. Abnormalities in adrenal androgens, but not of glucocortio-coids, in early Alzheimer's disease. Psychoneuroendocrinol 20: 83-94 (1995).
61. Hatfield CF, Herbert J, van Someren EJW, Hodges JR, Hastings MH. Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia. Brain 127: 1061-1074 (2004).
62. Popp J, Schaper K, Kolsch H, Cvetanovska G, Rommel F, Kling-muller D, et al. CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 30: 498-500 (2009).
63. Lightman SL, Conway-Campbell B. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci 11: 710-718 (2010).
64. Martensz ND, Herbert J, Stacey PM. Factors regulating levels of cortisol in cerebrospinal fluid of monkeys during acute and chronic hypercortisolemia. Neuroendocrinol 36: 39-48 (1983).
65. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Glucocorticoid feedback resistance, Trends Endocrinol Metab 8: 26-33 (1997).
66. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Brain corticosteroid receptor balance in health and disease. Endocrine Rev 19: 269-301 (1998).
67. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 160: 1554-165 (2003).
68. De Kloet ER, Fitzsimmons CP, Datson NA, Meijer OC, Vreugdenhil E. Glucocorticoid signaling and stress-related limbic susceptibility pathway: about receptors, transcription machinery and microRN A. Brain Res 1293: 129-141 (2009).
69. Newell-Price J, Trainer P, Basser M, Grossman A. The diagnosis and differential diagnosis of Cushing's Syndrome and Pseudo-Cushing's states. Endocrine Rev 19: 647-672 (1998).
70. Samuels MH, Brandon DD, Isabelle LM, Cook DM, Graham KE, Purnell JQ, et al. Cortisol production rates in subjects with suspected Cushing's syndrome: assessment by stable isotope dilution methodology and comparison to other diagnostic methods. J Clin Endocrinol Metab 85: 22-28 (2000).
71. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation of hyper-cortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 97: 325-330 (2000).
72. Stone AA, Schwartz JE, Smyth J, Kirschbaum C, Cohen S, Hell-hammer D, et al. Individual differences in the diurnal cycle of salivary cortisol: a replication of flattened cycles for some individuals. Psychoneuroendocrinol 26: 295-306 (2001).
73. Fairchild G, Leitch MM, Ingram CD. Acute and chronic effects of corticosterone on 5-HT1A receptor-mediated autoinhibition in the rat dorsal raphe nucleus. Neuropharmacol 45: 925-934 (2003).
74. Gartside SE, Leitch MM, Young AH. Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. Neuropsycho-pharmacol 28: 1572-1578 (2003).
75. Larsson CA, Gullberg B, Rastam L, Lindblad U. Salivary cortisol differs with age and sex and shows inverse associations with WHR in Swedish women: a cross-sectional study. BMC Endocr Disord 9: 16 (2009).
76. Lupien SJ, Lecours AR, Schwartz G, Shama S, Hauger RL, Meaney MJ, et al. Longitudinal study of basal cortisol levels in healthy elderly subjects: evidence for subgroups. Neurobiol Aging 97:95-105 (1996).
77. Sato H, Takahashi T, Sumitani K, Takatsu H, Urano S. Glucocorti-coid generates ROS to induce oxidative injury in the hippocampus, leading to impairment of cognitive function of rats. J Clin Biochem Nutr 47: 224-232 (2010).
78. Conrad CD. Chronic stress-induced hippocampal vulnerability: the glucocorticoid vulnerability hypothesis. Rev Neurosci 19: 395-411 (2008).
79. Sappolsky RM, Krey LC, McEwen BS. Stress down-regulates corticosterone receptors in a site-specific manner in the brain. En-docrinol 114: 287-292 (1984).
80. Seckl JR, French KL, O'Donnell D, Meaney MJ, Nair NPV, Yates CM, et al. Glucocorticoid receptor gene expression is unaltered in hippocampal neurons in Alzheimer's disease. Mol Brain Res 18: 239-245 (1993).
81. Wetzel DM, Bohn MC, Kazee AM, Hamill RW. Glucocorticoid receptor mRNA in Alzheimer's disease hippocampus. Brain Res 679: 72-81 (1995).
82. Tornello S, Orti E, DeNicola AF, Rainbow TC, McEwen BS. Regulation of glucocortiocid receptors in brain by corticosterone treatment of adrenalectomized rats. Neuroendocrinol 35: 411-417 (1982).
83. Herman JP, Spencer R. Regulation of hippocampal glucocorticoid receptor gene transcription and protein expression in vivo. J Neuro-sci 18: 7462-7473 (1998).
84. Mizoguchi K, Ishige A, Aburada M, Tabira T. Chronic stress attenuates glucocorticoid negative feedback: involvement of the pre-frontal cortex and the hippocampus. Neuroscience 119: 887-897 (2003).
85. Sapolsky RM, McEwen BS. Downregulation of neural corticoster-one receptors by corticosterone and dexamethasone. Brain Res 339: 161-165(1985).
86. Deak T, Nguyen KT, Cotter CS, Fleshner M, Watkins LR, Maier SF, et al. Long-term changes in mineralocorticoid anad glucocorti-coid receptor occupancy following exposure to an acute stressor. Brain Res 847: 211-20 (1999).
87. Paskitti ME, McReary BJ, Herman P. Stress regulation of adreno-corticosteroid receptor gene transcription and mRNA expression in rat hippocampus: time-course analysis. Mol Brain Res 80: 142-152 (2000).
88. Herman JP, Watson SJ, Chao HM, Coirini H, McEwen BS. Diurnal regulation of glucocorticoid receptor and mineralocorticoid receptor mRNAs in rat hippocampus. Mol Cell Neurosci 4: 181-190 (1993).
89. Webster MJ, Knable MB, O'Grady J, Orthmann J, Weickert CS. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 7: 985-994 (2002).
90. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, et al. Amyloid-p: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-p. Brain Res Rev 43: 1-16 (2003).
91. 2+ accumulation. Proc Natl Acad Sci USA 92: 9328-9332 (1995).
92. Okamoto K, Tanaka H, Ogawa H, Makino Y, Eguchi H, Hayashi S-I, et al. Redox-dependent regulation of nuclear import of the glucocorticoid receptor. J Biol Chem 274: 10363-10371 (1999).
93. Makino Y, Okamoto K, Yoshikawa N, Aoshima M, Hirota K, Yodoi J, et al. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. J Clin Invest 98: 2469-2477 (1996).
94. Makino Y, Oshikawa N, Okamoto K, Hirota K, Yodoi J, Makino I, et al. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem 274: 3182-3188 (1999).
95. Kitagawa H, Yamaoka I, Akimoto C, Kase I, Mezaki Y, Shimizu T, et al. A reduction state potentiates the glucocorticoid response through receptor protein stabilization. Genes Cells 12: 1281-1287 (2007).
96. Asaba K, Iwasaki Y, Yoshida M, Asai M, Oiso Y, Murohara T, et al. Glucocorticoid supression on proopiomelanocortin gene expression pituitary corticotroph cells. Endocrinology 145: 39-42 (2004).
97. Acker H. The oxygen sensing signal cascade under the influence of reactive oxygen species. Phil Trans R Soc B 360: 2201-2210 (2005).
98. 2+ and ROS. Front Biosci 14: 1197-1218 (2009).
99. You JM, Sun SJ, Nam KN, Kang C, Won R, Lee EH. Mechanism of glucocorticoid-induced oxidative stress in rat hippocampal slice cultures. Can J Physiol Pharmacol 87: 440-447 (2009).
100. Srivastava A, Baxi M, Yada S, Agarwal A, Gupta RK, Misram SK, et al. Juvenile rheumatoid arthritis with amyloid goiter: report of a case with review of the literature. Endocr Pathol 12: 437-441 (2001).
101. Poncin S, Colin IM, Gerard A-C. Minimal oxidative load: a prerequisite for thyroid cell function. J Endocrinol 201: 161-167 (2009).
102. Muller JM, Rupec RA, Baeuerle PA. Study of gene regulation by NF-kB and AP-1 in response to reactive oxygen intermediates. Methods 11: 301-312 (1997).
103. Avshalumov MV, Rice ME. NMDA receptor activation mediates hydrogen peroxide-induced pathophysiology in rat hippocampal slices. J Neurophysiol 87: 2896-2903 (2002).
104. Varghese K, Molnar P, Das M, Bhargava N, Lambert S, Kindy MS, et al. A new target for amyloid beta toxicity by standard and high-throughput electrophysiology. PLoS ONE 5: e8643 (2010).
105. Vereker E, O'Donnell E, Lynch A, Kelly A, Nolan Y, Lynch MA. Evidence that interleukin-1 p and reactive oxygen species production play a pivotal role in stress-induced impairment of LTP in the rat dentate gyrus. Eur J Neurosci 14: 1809-11819 (2001).
106. Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal axis during viral infection. Viral Immun 18: 41-78 (2005).
107. Pace TWW, Miller AH. Cytokines and glucocorticoid receptor signaling: relevance to major depression. Ann NY Acad Sci 1179: 86-105 (2009).
108. Remans PH, Gringhuis SI, van Laar JM, Sanders ME, Papendrecht van der Voort EAM, Zwartkruis FJT, et al. Rap1 signaling is required for suppression of Ras-generated reactive oxygen species and protection against oxidative stress in T lymphocytes. J Immunol 173: 920-31 (2004).
109. Jekabsone A, Mander PK, Tickler A, Sharpe M, Brown GC. Fibrillar beta amyloid peptide Ap1-40 activates microglial proliferation via stimulating TNF-a release and H2O2 derived from NADPH oxidase: a cell culture study. J Neuroinflamm 3: 24 (2006).
110. Tahara K, Kim H-D, Jin J-J, Maxwell A, Li L, Fukuchi K. Role of toll-like receptor signalling in Ap uptake and clearance. Brain 129: 3006-3019 (2006).
111. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Comm 273: 5-9 (2000).
112. Sierra A, Gottfried-Blackmore A, Milner TA, McEwen BS, Bulloch K. Steroid hormone receptor expression and function in microglia. Glia 56: 659-674 (2008).
113. Glezer I, Simard AR, Rivest S. Neuroprotective role of the innate immune system by microglia. Neurosci 147: 867-883 (2007).
114. Sorrells SF, Sapolsky RM. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 21: 259-272 (2006).
115. Frank MG, Miguel ZD, Watkins LR, Maier SF. Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E coli lipopolysaccharide. Brain Behav Immun 24: 19-30 (2010).
116. De Pablos RM, Villaran RF, Arguelles S, Herrera AJ, Venero JL, Ayala A, et al. Stress increases vulnerability to inflammation in the rat prefrontal cortex. Neurobiol Dis 26: 5709-5719 (2006).
117. Yang T-T, Tsao C-W, Li J-S, Wu H-T, Hsu C-T, Cheng J-T. Changes of dopamine content and cell proliferation by dexametha-sone via pituitary adenylate cyclase-activating polypeptide in PC 12 cell. Neurosci Lett 426: 45-48 (2007).
118. See V, Koch B, Loeffler JP. C2-ceramide and reactive oxygen species inhibit pituitary adenylate cyclase activating polypeptide (PACAP)-induced cyclic-AMP-dependent signalling pathway. J Neurochem 76: 778-788 (2001).
119. Kojro E, Postina R, Buro C, Meiringer C, Gehrig-Burger K, Fahr-enholz F. The neuropeptide PACAP promotes the a-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J 20: 512-514 (2006).
120. Rat D, Schmitt U, Tippmann F, Dewachter I, Theunis C, Wieczer-zak E, et al. Neuropeptide pituitary adenylate cyclase-activating peptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J 25: 3208-3218 (2006).
121. Acquaah-Mensah GK, Taylor RC, Bhave SV. PACAP interactions in the mouse brain: implications for behavioural and other disorders. Gene 491: 224-231 (2012).
122. Onoue S, Endo K, Oshima K, Yajima T, Kashimoto K. The neuropeptide PACAP attenuates beta-amyloid (1-41)-induced toxicity in PC12 cells. Peptides 23: 1471-1478 (2002).
123. Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, et al. 3D comparison of hippocampal atrophy in amnestic mold cognitive impairment and Alzheimer's disease. Brain 129: 2867-2873 (2006).
124. Karssen AM, Meijer OC, Berry A, Sanjuan Piñol R, de Kloet ER. Low doses of dexamethasone can produce a hypercorticosteroid state in the brain. Endocrinology 146: 5587-5595 (2005).
125. Brunson KL, Eghbal-Ahmadi M, Bender R, Chen Y, Baram TZ. Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress. Proc Natl Acad Sci USA 98: 8856-8861 (2001).
126. Van Haarst AD, Oitzl MS, Workel JO, de Kloet ER. Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity. Endocrinology 137: 4935-4943 (1996).
127. O'Brien JT, Ames D, Schweitzer I, Mastwyk M, Colman P. Enhanced adrenal sensitivity to adrenocorticotrophic hormone (ACTH) is evidence of HPA axis hyperactivity in Alzheimer's disease. Phys Med 26: 7-14 (1996).
128. Rivest S, Laflamme N, Nappi RE. Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. J Neurosci 15: 2690-2695 (1995).
129. Dyall SC. Amyloid-beta peptide, oxidative stress and inflammation in Alzheimer's disease: potential neuroprotective effects of omega-3 polyunsaturated fatty acids. Int J Alzheimers Dis 2010: Article ID 274128.
130. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosomat Res 53: 865-871 (2002).
131. Ziegler DR, Herman JP. Neurocircuitry of stress integration: anatomical pathways regulating the hypothalamo-pituitary-adrenocortical axis of the rat. Integ Comp Biol 42: 541-551 (2002).
132. Makino S, Gold PW, Schulkin J. Corticosterone effects on corticotropin-releasing hormone messenger RNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus. Brain Res 640: 105-112 (1994).
133. Makino S, Gold PW, Schulkin J. Effects of corticosterone on CRH mRNA and content in the bed nucleus of the stria terminalis; comparison with the effects in the central nucleus of the amygdala and the paraventricular nucleus of the hypothalamus. Brain Res 657: 141-149 (1994).
134. Vellucci SV, Parrott RF. Hipocampal gene expression in the pig: upregulation of corticotrophin -releasing hormone mRNA following central administration of the peptide. Neuropeptides 34: 221-228 (2000).
135. Reyes BAS, Valentino RJ, Xu G, Van Bockstaele EJ. Hypotha-lamic projections to locus coeruleus neurons in rat brain. Eur J Neurosci 22: 93-106 (2005).
136. Mansi JA, Rivest S, Frolet G. Regulation of corticotropin-releasing factor type 1 (CRF1) receptor messenger ribonucleic acid in the paraventricular nucleus of rat hypothalamus by exogenous CRF. Endocrinology 137: 4619-4629 (1996).
137. Ono N, Bedran de Castro JC, McCann SM. Ultrashort-loop positive feedback of corticotropin (ACTH)-releasing factor to enhance ACTH release in stress. Proc Natl Acad Sci USA 82: 3528-3531(1985).
138. Imaki T, Katsamuta H, Konishi S-I, Kasagi Y, Minami S. Cortico-tropin-releasing factor type-1 receptor mRNA is not induced in mouse hypothalamus by either stress or osmotic stimulation. J Neu-roendocrinol 15: 916-924 (2003).
139. Yan X-X, Toth Z, Schults L, Ribak CE, Baram TZ. Corticotropin-releasing hormone (CRH)-containing neurons in the immature rat hippocampal formation: light and electron microscopic features and colocalization with glutamate decarboxylase and parvalbumin. Hippocampus 8: 231-243 (1998).
140. Chen Y, Bender RA, Frotscher M, Baram TZ. Novel and transient populations of corticotropin-releasing hormone-expressing neurons in developing hippocampus suggest unique functional roles: a quantitative spatiotemporal analysis. J Neurosci 21: 7171-7178 (2001).
141. Chen Y, Dube CM, Rice CJ, Baram TZ. Rapid loss of dendritic spines after stress involves derangement of spine dynamics by cor-ticotropin-releasing hormone. J Neurosci 28: 2903-2911 (2008).
142. Ivy AS, Rex CS, Chen Y, Dube C, Maras PM, Grigoriadis DE, et al. Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors, J Neurosci 30 13005-13015 (2010).
143. Hatalski CG, Brunson KL, Tantayanubutr B, Chen Y, Baram TZ. Neuronal activity and stress differentially regulate hippocampal and hypothalamic corticotropin-releasing hormone expression in the immature rat. Neurosci 101: 571-580 (2000).
144. Adzic M, Djordjevic J, Nicitorovic A, Demonacos C, Radojcic M, Krstic-Demonacos M. Acute or chronic stress induce cell compartment-specific phosphorylation of glucocorticoid receptor and alter its transcriptional activity in Wistar rat brain. J Endocrinol 202: 87-97 (2009).
145. Lu NZ, Cidlowski JA. Glucocorticoid receptor isoforms generate transcriptional specificity. Trends Cell Biol 16: 301-307 (2006).
146. Chen W, Dang T, Blind RD, Wang Z. Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol 22: 1754-1766 (2008).
147. Meng Q-Y, Chen X-N, Tong D-L, Zhou J-N. Stress and glucocorti-coids regulated corticotropin releasing factor in rat prefrontal cortex. Mol Cell Endocrinol 342: 54-63 (2011).
148. Chappell PB, Smith MA, Kilts CD, Bissette G, Ritchie J, Anderson C, et al. Alterations in corticotropin-releasing factor-like im-munoreactivity in discrete brain regions after acute and chronic stress. J Neurosci 6: 2908-2914 (1986).
149. Piekut DT, Phipps B. Increased corticotropin-releasing factor im-munoreactivity in select brain sites following kainite-elicited seizures. Brain Res 781: 100-113 (1998).
150. De Souza CP. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinol 20: 789-819 (1995).
151. Gallagher JP, Orozco-Cabal LF, Shinnick-Gallagher P. Synaptic physiology of central CRH system. Eur J Pharmacol 583: 215-225 (2008).
152. Powers RE, Walker LC, De Souza EB, Vale WW, Struble RG, Whitehouse PJ, et al. Immunohistochemical study of neurons containing corticotropin-releasing factor in Alzheimer's disease. Synapse 1: 405-410 (1987).
153. Kelley M, Kowall N. Corticotropin-releasing factor immunoreac-tive neurons persist throughout the brain in Alzheimer's disease. Brain Res 501: 392-396 (1989).
154. Kling MA, Roy A, Doran AR, Calabrese JR, Rubinow DR, Whit-field Jr HJ, et al. Cerebrospinal fluid immunoreactive corticotrophin releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications. J Clin Endocrinol Metab 72: 260-271 (1991).
155. Bissette G, Reynolds GP, Kilts CD, Wilderov W, Nemeroff CB. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. JAMA 254: 3067-3069 (1985).
156. Horgan J, Miguel-Hidalgo JJ, Thrasher M, Bissette G. Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (Tg2576) model of Alzheimer's disease. Alzheimer's Dis 12: 115-127 (2007).
157. Branson KL, Grigoriadis DE, Lorang MT, Baram TZ. Corticotro-pin-releasing hormone (CRH) downregulates the function of its receptor (CRF1) and induces CRF1 expression in hippocampal and cortical regions of the immature rat brain. Exp Neurol 176: 75-86 (2002).
158. Gallopin T, Geoffrey H, Rossier J, Lambolez B. Cortical sources of CRF, NKB, and CCK and their effects onpyramidal cells in the neocortex. Cereb Cortex 16: 1440-1452 (2006).
159. Fertuzinhos S, Krsnik Z, Kawasawa YI, Rasin M-R, Kwan KW, Chen J-G, et al. Selective depletion of molecularly defined cortical interneurons in human holoprosencephaly with severe striatal hy-poplasia. Cereb Cortex 19: 2196-2207 (2009).
160. Biegon A, Alvarado M, Budinger TF, Grossman R, Hensley K, West MS, et al. Region-selective effects of neuroinflammation and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors in the rat brain. J Neurochem 82: 924-934 (2002).
161. Patel PD, Lopez JF, Lyons DM, Burke S, Wallace M, Schatzberg AF. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res 34: 383-392 (2000).
162. Sanchez MM, Young L, Plotsky P, Insel TR. Distribution of corti-costeroid receptors in the rhesus brain: relative absence of gluco-corticoid receptors in the hippocampal formation. J Neurosci 20: 657-668 (2000).
163. Kremen WS, O'Brien RC, Panizzon MS, Prom-Wormley E, Faves LJ, Eisen SA, et al. Salivary cortisol and prefrontal cortical thickness in middle-aged men: a twin study. Neuroimage 53: 1093-1102 (2010).
164. Du A-T, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini LM, Rankin K, et al. Different regional patters of cortical thinning in Alzheimer's disease and frontotemproal dementia. Brain 130: 1159-1166 (2007).
165. Lace G, Savva GM, Forster G, de Silva R, Brayne C, Matthews FE, et al. Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain 132: 1324-1334 (2009).
166. Charney DS, Grillon C, Bremmer JD. The neurobiological basis of anxiety and fear: circuits, mechanisms, and neurochemical interactions (Part I). Neuroscientist 4: 35-44 (1998).
167. Mezey E, Palkovits M. Meningeal relations of the rat hypothalamo-hypophyseal system. Extravascular fluid spaces in and around the median eminence. Brain Res 250: 21-30 (1982).
168. Rodriguez EM, Blazquez JL, Guerra M. The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid. Peptides 31: 757-76 (2010).
169. Bissette G, Klimek V, Pan J, Stockmaier C, Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacol 28: 1328-35 (2003).
170. Newport DJ, Helm C, Owens MJ, Ritchie JC, Ramsay CH, Bonsall R, et al. Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. Neuropsycho-pharmacol 28: 569-576 (2003).
171. 14C]inulin in rat. Neurosci 95: 577-592 (2000).
172. Ghersi-Egea J-F, Finnegan W, Chen J-L, Fenstermacher JD. Rapid distribution of intraventricularly administered sucrose into cerebro-spinal fluid cisters via subarachnoid velae in rat. Neurosci 75: 1271-1288 (1996).
173. Clarke M, Weiss SRB, Post RM. Expression of c-fos mRNA in rat brain after intracerebroventricular administration of corticotropin-releasing hormone. Neurosci Lett 132: 235-238 (1991).
174. Justice NJ, Yuan ZF, Sawchenko PE, Vale W. Type 1 corticotro-pin-releasing factor receptor expression reported in BAC transgenic mice: implications for reconciling ligand-receptor mismatch in the central CRF system. J Comp Neurol 2511: 479-496 (2008).
175. Millan MA, Jacobowitz DM, Hauger RL, Catt KJ, Aguilera G. Distribution of corticotropin-releasing factor receptors in primate brain. Proc Natl Acad Sci USA 383: 1921-1925 (1986).
176. Sanchez MM, Young L, Plotsky P, Insel TR. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 408: 365-377 (1999).
177. Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol 121: 589-595 (2011).
178. Fries W, Keizer K, Kuypers HG. Large layer VI cells in macaque striate cortex (Meynert cells) project to both superior colliculus and prestriate visual area V5. Exp Brain Res 58: 613-616 (1985).
179. Dufourny L, Skinner DC. Type II glucocorticoid receptors in the ovine hypothalamus: distribution, influence of estrogen and absence of co-localization with GnRH. Brain Res 946: 79-86 (2002).
180. Tsolakidou A, Czibere L, Outz B, Trumbach D, Panhuysen M, Deussing JM, et al. Gene expression profiling in the stress control brain region hypothalamic paraventricular nucleus reveals a novel gene network including Amyloid beta precursor protein. Genomics 11: 546 (2010).
181. Müller H, Schweitzer N, Johren O, Dominiak P, Raasch W. Angio-tensin II stimulates the reactivity of the pituitary-adrenal axis in leptin-resistant Zucker rats, thereby influencing the glucose utilization. Am J Physiol Endocrinol Metab 293: 802-810 (2007).
182. Armando I, Volpi S, Aguilera G, Saavedra JM. Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res 1142: 92-99 (2007).
183. Pavel J, Benicky J, Larrayoz-Roldan I, Murukami Y, Sanchez-Lemus E, Zhou J, et al. Peripherally administered Angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Ann NY Acad Sci 1148: 360-366 (2008).
184. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363: 1139-1146 (2004).
185. Li N-C, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340: b5465 (2010).
186. Armando I, Carranza A, Nishimura Y, Hoe KL, Barontoni M, Terron JA, et al. Peripheral administration of an Angiotensin II AT1 receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation stress. Endocrinology 142: 3880-3889 (2001).
187. Pavlatou M. Chronic administration of angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. Stress 11: 67-72 (2007).
188. Reyland ME, Gwynne JT, Forgez P, Prack MM, Williams DL. Expression of the human apolipoprotein E gene suppresses steroi-dogenesis in mouse Y1 adrenal cells. Proc Natl Acad Sci USA 88: 2375-2379 (1991).
189. -/-mice: possible role in behavioural and metabolic alterations. Neurosci 20: 2064-2071 (2000).
190. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 89: 4471-4475 (1992).
191. Grootendorst J, Enthoven L, Dalm S, de Kloet ER, Oitzl MS. Increased corticosterone secretion and early-onset of cognitive decline in female apolipoprotein E-knockout mice. Behav Brain Res 148: 167-77 (2004).
192. Lominska C, Levin JA, Wang J, Sikes J, Kao C, Smith JD. Apol-ipoprotein E deficiency effects on learning in mice are dependent upon the background strain. Behav Brain Res 120: 23-34 (2001).
193. Raber J, Wong D, Butini M, Orth M, Bellosta S, Pitas RF, et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci USA 95: 10914-10919 (1998).
194. Gallo PV, Weinberg J. Corticosterone rhythmicity in the rat: interactive effects of dietary restriction and schedule of feeding. J Nutr 111: 208-218 (1981).
195. Patel NV, Finch CE. The glucocorticoid paradox of caloric restriction in slowing brain aging. Neurobiol Aging 23: 707-717 (2002).
196. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, et al. Caloric restriction attenuates p-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 19: 659-661 (2005).
197. Quin W, Chachich M, Lane M, Roth G, Bryant M, de Cabo R, et al. Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus), J Alzheimer's Dis 10: 417-422 (2006).
198. Halagappa VKM, Guo Z, Pearson M, Matsuoka Y, Cutler RG, LaFerla FM, et al. Intermittent fasting and caloric restriction ameliorate age-related behavioural deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol Dis 26: 212-220 (2007).
199. Lee BK, Glass TA, Wand GS, McAtee MJ, Bandeen-Roche K, Bolla KI, et al. Apolipoprotein E genotype, cortisol, and cognitive function in community-dwelling older adults. Am J Psychiatry 165: 1456-1464 (2008).
200. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 300: 7-16 (2009).
201. Van Rossum EFC, Koper JW, Huizenga NATM, Utterlinden AG, Janssen JAMJL, Brinkmann AO, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels, Diabetes 51: 3128-3134 (2002).
202. Meaney MJ, Diorio J, Francis D, Widdowson J, LaPlante P, Caldji C, et al. Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress. Dev Neurosci 18: 49-72 (1996).
203. Kapoor A, Leen J, Matthews SG. Molecular regulation of the hypo-thalamic-pituitary-adrenal axis in adult male guinea pigs after prenatal stress at different stages of gestation. J Physiol 586: 4317-4326 (2008).
204. Olsson T, Mohammed AH, Donaldson LC, Henriksson BG, Seckl JR. Glucocorticoid receptor and NGFI-A gene expression are induced in the hippocampus after environmental enrichment in adult rats. Mol Brain Res 23: 349-353 (1994).
205. Larsson F, Winblad B, Mohammed AH. Psychological stress and environmental adaptation in enriched vs. impoverished housed rats. Pharmacol Biochem Behav 73: 193-207 (2002).
206. Weaver ICG. Epigenetic reprogramming by maternal behavior and pharmacological intervention. Nature versus nurture: lets call the whole thing off. Epigenetics 2: 22-8 (2007).
207. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonté B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 12: 342-348 (2009).
208. Spencer RL, Young EA, Choo PH, McEwen BS. Adrenal steroid type I and type II receptor binding: estimates of in vivo number, occupancy, and activation with varying level of steroid. Brain Res 514: 37-48 (1990).
209. Meaney MJ, Lupien SJ. Hippocampus, overview. In (Ed: Fink G). Encyclopedia of stress, volume 2. San Diego: Elsevier pp.379-385 (2000).
210. Young EA Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 83: 3339-3345 (1998).
211. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. Antihypertensive medication use and incident Alzheimer disease. Arch Neurol 63: 686-692 (2006).
212. Arvat E, Maccagno B, Giordano R, Pellegrino M, Broglio F, Gianotti L, et al. Mineralocorticoid receptor blockade by can-renoate increases both spontaneous and stimulated adrenal function in humans. J Clin Endocrinol Metab 86: 3176-3181 (2001).
213. Höschl C, Hajek T. Hippocampal damage mediated by corticosteroids - a neuropsychiatric research challenge. Eur Arch Psychiatry Clin Neurosci 251: Suppl 2, 1181-1188 (2001).
214. Chavant F, Deguil J, Pain S, Ingrand I, Perault-Pochat MC, Lafay-Chebassier C. Imipramine, in part through TNF-a inhibition, prevents cognitive decline and Aβ accumulation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 332: 505-514 (2010).
215. Tobinick EL, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Med Gen Med 8: 25 (2006).
216. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflamm 5: 2 (2008).
217. Breitner JCS, Haneuse SJPA, Walker R, Dublin S, Crane PK, Gray SL, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72: 1899-1905 (2009).
218. MacKenzie IRA. Anti-inflammatory drugs and Alzheimer-type pathology in aging. Neurology 54: 732-767 (2000).